Boinca Therapeutics

Boinca Therapeutics is a UK-based biotechnology company specializing in the development of next-generation senolytic therapies to treat aging-related diseases and cancer. Spun out from the University of Leicester, the company leverages a proprietary platform to identify specific surface markers that are uniquely expressed on senescent cells. This approach allows for the highly targeted clearance of these "zombie cells" while sparing healthy tissue, addressing the toxicity limitations of first-generation senolytics. The company's pipeline is currently focused on pre-clinical programs for idiopathic pulmonary fibrosis and oncology indications. Boinca aims to utilize various delivery modalities, including antibody-drug conjugates and encapsulated small molecules, to improve therapeutic outcomes in age-related degeneration.